FDA rejects cortisol modulator for hypertension, citing need for additional data despite trial success, delaying approval for Corcept ...

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...

Impressively, the unit registered the lowest frequency loss of any chip to date. Specifically, the engineers noted that the new chip was 15x more stable and 100x more efficient in terms of microwave ...

AXS-12's clinical development program in narcolepsy includes three controlled efficacy trials, and a completed long-term safety trial. The drug has already been granted orphan drug designation, a ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...

As of Monday, December 29, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 5.24%, which has investors questioning ...

Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a ...

Axsome Therapeutics (AXSM) received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting an NDA ...

That five minute interaction kept coming to mind as I read Edwidge Danticat’s beautiful memoir, Brother, I’m Dying.

Researchers at Carnegie Mellon University have developed a groundbreaking lens technology that enables a camera to focus on ...

A new microchip-sized device could dramatically accelerate the future of quantum computing. It controls laser frequencies ...